DSM Capital Partners’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
|
|||||
|
2024
Q4 | $127M | Sell |
|
|||||
|
2024
Q3 | $109M | Sell |
|
|||||
|
2024
Q2 | $137M | Sell |
|
|||||
|
2024
Q1 | $157M | Sell |
|
|||||
|
2023
Q4 | $161M | Sell |
|
|||||
|
2023
Q3 | $138M | Buy |
|
|||||
|
2023
Q2 | $100M | Sell |
|
|||||
|
2023
Q1 | $127M | Sell |
|
|||||
|
2022
Q4 | $159M | Buy |
|
|||||
|
2022
Q3 | $140M | Sell |
|
|||||
|
2022
Q2 | $130M | Sell |
|
|||||
|
2022
Q1 | $127M | Sell |
|
|||||
|
2021
Q4 | $120M | Sell |
|
|||||
|
2021
Q3 | $145M | Sell |
|
|||||
|
2021
Q2 | $149M | Buy |
|
|||||
|
2021
Q1 | $131M | Buy |
|
|||||
|
2020
Q4 | $107M | Buy |
|
|||||
|
2020
Q3 | $80.5M | Sell |
|
|||||
|
2020
Q2 | $106M | Buy |
|
|||||
|
2020
Q1 | $74.4M | Buy |
|
|||||
|
2019
Q4 | $72.1M | Buy |
|
|||||
|
2019
Q3 | $58.7M | Sell |
|
|||||
|
2019
Q2 | $55.8M | Sell |
|
|||||
|
2019
Q1 | $61.3M | Buy |
|